MEF2C and breast cancer: The key findings ensuing from this work, schematically depicted in Figure 5, pave the way for future studies directed at the exploitation of MEF2C as a biomarker of BCBM development and prognosis, as well as of the associated signaling pathways as potential therapeutic targets, which will, hopefully, improve the expectancy and QoL of BC patients.